QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma Clinical Trial

Official title:

A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01670994
• Other study ID #: CA-ALT-801-01-11
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: August 14, 2012
• Est. completion date: September 9, 2015

Study information

• Verified date: May 2024
• Source: Altor BioScience
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 in patients who have relapsed or refractory multiple myeloma.

Description:

Multiple Myeloma (MM) is a plasma cell malignancy that makes up 1% of all cancers and 10% of hematologic neoplasma, and is the second most commonly diagnosed hematologic malignancy. There are an estimated 20,520 new cases of MM and 10,610 deaths due to MM in the United States. Historically, standard first-line therapy for MM consisted of combination therapy with an alkylating agent, such as melphalan and prednisone. Response rates with such combination therapy are approximately 50%, but five-year survival rates remain low at 33%. For younger patients, debulking chemotherapy followed by autologous stem cell transplant (ASCT) with melphalan is the treatment of choice to increase the potential for a sustained durable remission. However, a large percentage of patients diagnosed with MM are not suitable candidates for ASCT because of age or comorbidities. The approach to MM treatment has undergone a radical transformation over the past decade with the introduction of the proteasome inhibitor, bortezomib, and immunomodulatory drugs (ImiDs), thalidomide or lenalidomide. Despite some advances in the treatment of MM, the disease remains incurable due to the persistence of minimal residual disease. Thus, novel modalities complementing or improving current treatment options are needed.

There is ample evidence that immunomodulatory drugs are effective against myeloma. Lenalidomide and thalidomide have been shown to stimulate T cells in the presence of antigen presenting cells via costimulatory pathway. Also, modulation of NK cell function has been associated with anti-tumor activity observed in MM patients treated with lenalidomide. It has been demonstrated that NK cells exhibit potent anti-MM activity following IL-2 administration, and ex vivo IL-2-activated and intravenously administered NK cells prolong survival in MM-bearing mice. Thus further demonstrating the role and importance of NK cells in the treatment of MM. Taken together, these data suggest that the use of a potent immunotherapeutic is an attractive approach to provide durable immune responses to or even potentially curing patients with MM.

Additionally, immunotherapy is a well-established approach for treating other cancer types. One strategy that has received attention is treatment with cytokines such as IL-2 to enhance anti-tumor immunity. Unfortunately, the considerable toxicity associated with this treatment makes it difficult to achieve an effective dose at the site of the tumor and limits the population that can be treated. Thus, there is a critical need for innovative strategies that enhance the effects of IL-2, reduce its toxicity without compromising clinical benefit, provide a more convenient dosing regimen, and treat other diagnoses including MM.

Altor Bioscience Corp. has developed a tumor-targeted IL-2 fusion protein, ALT-801, comprising human recombinant IL-2 genetically linked to a TCR domain capable of binding a tumor associated human p53 peptide presented in the context of HLA-A2.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: September 9, 2015
• Est. primary completion date: September 9, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

ENTRY CRITERIA:

DISEASE CHARATERISTICS:

• Confirmed diagnosis of relapsed/refractory multiple myeloma after treatment with at least two different previous regimens.

• Refractory disease is defined as progressive disease while on therapy or progression within 60 days of therapy.

• Progressive disease is defined by a 25% increase from the lowest response value in specified tests.

• Measurable disease as defined by at least one of the following:

• Serum M-protein = 1g/dL (for IgG, IgM) or 0.5 g/dL (for IgA)

• Urine M-protein = 200mg/24hours

• Serum free light chains = 10 mg/dL and abnormal kappa/lambda ratio

PRIOR/CONCURRENT THERAPY:

• No anti-myeloma treatments within 28 days before the start of study treatment.

• Must have recovered from side effects of prior treatments.

PATIENT CHARACTERISTICS:

Age

• = 18 years

Performance Status

• ECOG 0, 1, or 2

Bone Marrow Reserve

• Absolute neutrophil count (AGC/ANC) = 1,000/uL

• Platelets = 30,000/uL

• Hemoglobin = 8g/dL

Renal Function

• Glomerular Filtration Rate (GFR) > 45mL/min/1.73m^2

Hepatic Function

• Total bilirubin = 2.0 X ULN

• AST, ALT, ALP = 3.0 X ULN, or = 5.0 X ULN (if liver metastases exist)

Cardiovascular

• No congestive heart failure < 6 months

• No unstable angina pectoris < 6 months

• No myocardial infarction < 6 months

• No history of ventricular arrhythmias

• No history of supraventricular arrhythmias

• No NYHA Class > II CHF

• Normal Transthoracic Echocardiogram (TTE) is required for patients with history of EKG abnormalities, CHF, coronary artery disease or other cardiac disease, or with a history of having received adriamycin or doxorubicin

• Patients with a left ventricular ejection fraction (LVEF) of less than 50% will be excluded from study entry

Pulmonary

• Normal clinical assessment of pulmonary function

Other

• Negative serum pregnancy test if female and of childbearing potential

• Women who are not pregnant or nursing

• Subjects, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the study

• No known autoimmune disease other than corrected hypothyroidism

• No known prior organ allograft or allogeneic transplantation

• Not HIV positive

• No history or evidence of uncontrollable CNS disease

• No psychiatric illness/social situation

• No other illness that in the opinion of the investigator would exclude the subject from participating in the study

• Must provide informed consent and HIPPA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations

• Active systemic infection requiring parenteral antibiotic therapy.

• No ongoing chronic systemic steroid therapy required.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Relapsed or Refractory Multiple Myeloma

Intervention

Biological:
• ALT-801
Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle

Locations

Country	Name	City	State
United States	University of Iowa Hospitals	Iowa City	Iowa

Sponsors (2)

Lead Sponsor	Collaborator
Altor BioScience	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Treatment-Related Adverse Events	Number of treatment related AEs that occur or worsen after the first dose of study treatment	7 weeks